Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TScan Therapeutics (TCRX)
NASDAQ:TCRX
TCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.99 - $9.69
Previous CloseN/A
Volume150.47K
Average Volume (3M)358.70K
Market Cap
$116.88M
Enterprise Value$410.36M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Mar 05, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding49,094,006
10 Day Avg. Volume574,440
30 Day Avg. Volume358,704
Standard Deviation0.27
R-Squared0.03
Alpha-0.00663
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.48
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap3.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.12
Enterprise Value/Ebitda-3.99
Forecast
1Y Price Target
$13.00Price Target Upside493.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
TScan Therapeutics News
PremiumCompany Announcements
TScan Therapeutics Secures $52.5M Loan from SVB
PremiumCompany Announcements
TScan Therapeutics Announces Promising Phase 1 Trial Results
PremiumCompany Announcements
TScan Therapeutics Reports Q3 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Market PotentialThe expected near-term US/EU market opportunity for TSC-101 ranges from approximately 1,000 to 5,000 patients.
Regulatory ProgressA pivotal study for TSC-101 is expected to begin using relapse-free survival as the primary endpoint.
Treatment EfficacyThe TSC arm outperformed the control arm with only 8% of patients relapsing compared to 33% in the control arm.
Bears Say
Development ChallengesResults presented at ASH provide significant clinical de-risking for TSC-101, yet the stock performance suggests market skepticism.
Market ConcernsThe driver of the pressure on TCRX following the data is unclear, but the lack of near-term catalysts may be challenging.
Stock PerformanceWhile the stock is trading down, the data in the presentation continued to show encouraging differences between the two arms.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $1.99 and its highest was $9.69 in the past 12 months.
What is TScan Therapeutics’s market cap?
TScan Therapeutics’s market cap is $116.88M.
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Mar 05, 2025 which is in 11 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.315 by $0.065.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -0.32.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 49,094,006 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.315. Following the earnings report the stock price went down -4.912%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Currently, no hedge funds are holding shares in TCRX
---
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (493.61% Upside)
$13.00 (493.61% Upside)
Blogger Sentiment
Bullish
TCRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $385.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.77%
12-Months-Change
Fundamentals
Return on Equity
-55.92%
Trailing 12-Months
Asset Growth
19.44%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
---
TCRX Stock 12 Month Forecast
Average Price Target
$13.00
▲(493.61% Upside)
Technical Analysis
Best Analysts Covering TCRX
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-1.16%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -1.16% per trade.
---